1. Home
  2. BILL vs TRVI Comparison

BILL vs TRVI Comparison

Compare BILL & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo BILL Holdings Inc.

BILL

BILL Holdings Inc.

HOLD

Current Price

$43.61

Market Cap

3.2B

Sector

Technology

ML Signal

HOLD

Logo Trevi Therapeutics Inc.

TRVI

Trevi Therapeutics Inc.

HOLD

Current Price

$17.37

Market Cap

2.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BILL
TRVI
Founded
2006
2011
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.2B
2.6B
IPO Year
2019
2019

Fundamental Metrics

Financial Performance
Metric
BILL
TRVI
Price
$43.61
$17.37
Analyst Decision
Buy
Strong Buy
Analyst Count
21
11
Target Price
$57.90
$21.55
AVG Volume (30 Days)
2.4M
3.0M
Earning Date
05-07-2026
05-05-2026
Dividend Yield
N/A
N/A
EPS Growth
74.07
31.91
EPS
0.07
N/A
Revenue
$1,462,570,000.00
N/A
Revenue This Year
$14.18
N/A
Revenue Next Year
$13.83
N/A
P/E Ratio
$589.43
N/A
Revenue Growth
13.36
N/A
52 Week Low
$31.41
$6.55
52 Week High
$57.21
$20.22

Technical Indicators

Market Signals
Indicator
BILL
TRVI
Relative Strength Index (RSI) 60.90 50.62
Support Level $42.06 $10.07
Resistance Level $46.70 $20.19
Average True Range (ATR) 1.86 1.40
MACD -0.01 -0.23
Stochastic Oscillator 67.97 27.89

Price Performance

Historical Comparison
BILL
TRVI

About BILL BILL Holdings Inc.

BILL Holdings Inc is a provider of software-as-a-service, cloud-based payments and spend and expense management products, which allow users to automate accounts payable and accounts receivable transactions, enable businesses to easily connect with their suppliers or customers to do business, eliminate expense reports, manage cash flows and improve back office efficiency. Initial Public Offering and Follow-on Offering.

About TRVI Trevi Therapeutics Inc.

Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, non-IPF interstitial lung disease, or non-IPF ILD, and refractory chronic cough, or RCC. Haduvio is an oral extended-release formulation of nalbuphine. The Company operates and manages its business as one reportable segment. Such a segment is the business of developing and commercializing the investigational therapy Haduvio.

Share on Social Networks: